Crossmark

Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants

Crossref DOI link: https://doi.org/10.1007/s00228-021-03264-0

Published Online: 2022-01-18

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bhagavathula, Akshaya Srikanth

Woolf, Benjamin

Rahmani, Jamal

Vidyasagar, Kota

Tesfaye, Wubshet https://orcid.org/0000-0001-7208-2330
License Information

Text and Data Mining valid from 2022-01-18

Version of Record valid from 2022-01-18
More Information

Article History

Received: 24 August 2021

Accepted: 9 December 2021

First Online: 18 January 2022

Declarations

:

: No ethical approval will be needed because data from previous published studies.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below